AZD9291 has significantly greater efficacy than that of platinum therapy plus pemetrexed or first‐line EGFR‐TKIs in patients with T790M‐positive advanced NSCLC.6, 7 However, NSCLC becomes resistance to AZD9291 treatment, and the resistance mechanisms can be divided into EGFR‐independent resistance mechanisms, such as the activation of HER2 or Met, and EGFR‐dependent resistance mechanisms, such as the EGFR C797S mutation.8, 9. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.